USE OF INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 7 AND TISSUE INHIBITOR OF METALLOPROTEINASE 2 IN THE MANAGEMENT OF RENAL REPLACEMENT THERAPY

摘要

The present invention provides methods and compositions for managing renal replacement therapy. A risk score, which is determined from a urinary concentration of IGFBP7 (insulin-like growth factor-binding protein 7) and/or a urinary concentration of TIMP-2 (tissue inhibitor of metalloproteinase 2), is determined obtained from the patient, and is used to manage patient treatment.